glp 1 receptor agonists are contraindicated in Safety and Tolerability of Glucagon-Like Peptide-1 Agonists: A State-of-the-Art Narrative Review | Drugs Current Insights, Advantages and Challenges
Description
Chinmay S Marathe, Endocrine and Metabolic Unit, Royal Adelaide Hospital, Adelaide, SA 5000, Australia
Cardiovascular and Kidney Protection: Optimizing 'Energy Allocation Priority' Patients with cardiovascular disease and chronic kidney disease (CKD) often experience energy metabolism disorders, manifested as insufficient energy supply to myocardial and renal tissues, increased oxidative stress, and intensified inflammatory reactions
Effects on classic cardiovascular risk factors CVOTs on GLP-1RAs Data from the major CVOTs ELIXA, SUSTAIN-6, EXSCEL, HARMONY, PIONEER 6, LEADER, REWIND, and AMPLITUDE-O [53, 54, 56, 5963] support the overall safety of GLP-1RAs relative to major cardiovascular outcomes
The benefits of a combined therapy have been confirmed in a few retrospective cohort studies
The demand for GLP-1 receptor agonists is growing due to the favorable policies from various government institutions across the globe
[DOI] [PubMed] [Google Scholar] 186.Vanbuskirk K.A., Potenza M.N
